Investing.com - Financial Markets Worldwide

AstraZeneca PLC (AZN)

Symbol
Exchange
Currency
AZN
LondonGBPReal-time
3LAZ
LondonGBPReal-time
3SAZ
LondonGBPReal-time
AZNl
BATS EuropeGBPDelayed
AZNs
BATS EuropeSEKDelayed
AZN
NASDAQUSDReal-time
AZNCF
OTC MarketsUSDDelayed
AZNN
MexicoMXNDelayed
AZN
StockholmSEKReal-time
AZN
FrankfurtEURDelayed
AZN
TradeGateEURDelayed
AZN
XetraEURDelayed
AZNPy
FrankfurtEURDelayed
AZN
Buenos AiresARSDelayed
1,086.2
+5.6(+0.52%)
-Closed.
Currency in SEK
  • Volume:
    571,280
  • Bid/Ask:
    0.0/0.0
  • Day's Range:
    1,081.6 - 1,090.0
  • Type:Equity
  • Market:Sweden
  • ISIN:GB0009895292
  • S/N:1549109281

AZN Overview

Prev. Close
1,080.6
Day's Range
1,081.6-1,090
Revenue
296.22B
Open
1,084
52 wk Range
790-1,102
EPS
-
Volume
571,280
Market Cap
1.68T
Dividend (Yield)
23.53
(2.39%)
Average Vol. (3m)
486,329
P/E Ratio
96.16
Beta
-
1-Year Change
23.61%
Shares Outstanding
1,549,400,665
Next Earnings Date
Feb 10, 2022
What is your sentiment on AstraZeneca PLC?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC News

AstraZeneca PLC Analysis

AstraZeneca PLC Company Profile

AstraZeneca PLC Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
76100
Market
United Kingdom

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; Proteros biostructures GmbH to discover and develop novel small molecules. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; and Scorpion Therapeutics, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. The company was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Income Statement

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellSellStrong BuyStrong BuyStrong Buy
SummaryStrong SellNeutralStrong BuyStrong BuyStrong Buy

Trending Stocks

Trending Stocks

Name
Last
High
Low
Chg.
Chg. %
Vol.
Time
Meta Platforms
322.67327.09319.33+4.52+1.42%15.17MNASDAQ
Apple
167.92171.08167.36-1.88-1.11%64.11MNASDAQ
Bank of America
46.5948.5846.35+0.32+0.70%59.87MNYSE
Alphabet A
2,735.712,759.192,715.64+15.75+0.58%946.07KNASDAQ
Tesla
1,009.771,054.67995.50-20.74-2.01%19.89MNASDAQ
Netflix
516.78523.21510.51+5.98+1.17%2.77MNASDAQ
NVIDIA
253.79265.43250.63-5.24-2.02%38.84MNASDAQ
Barrick Gold
20.0520.1918.76+1.50+8.05%27.84MNYSE
Centene
77.7379.9077.67-0.96-1.22%1.72MNYSE
Amazon.com
3,147.303,185.003,136.00-31.05-0.98%1.80MNASDAQ
Gartner
282.41286.53280.27+4.36+1.57%232.00KNYSE
First Majestic Silver
11.8211.9410.74+1.28+12.14%8.91MNYSE
Kinross Gold
5.916.005.53+0.430+7.85%22.91MNYSE
Moderna
175.44191.34175.11-11.17-5.99%7.93MNASDAQ
Suncor Energy
28.4228.9228.11-0.18-0.63%4.62MNYSE
  • An attractive PRE-IPO called SpectrumX based in England plans to launch by November and i'm very hopeful of this particular investment. Clinical trials for their Covid-19 respiratory treatment are now in phase 2 of development which will be a game changer once hospitals get their hands on it. This will not be factored into the company valuation when listed. So if the trials are successful the market value will rocket. Thats why im seriously excited about this IPO and i don't usually go near PRE IPO's.
    4
    • how's it doing today
      0
    • how's it doing today
      0
  • 50
    0
    • *50000
      0
  • 19970410🌍 10000%
    0
    • Most of vunerable demographic now vaccinated. Will younger people accept the jab or will potential health concerns outweigh the potential benefits. I'm short AstraZeneca
      4
      • net short positions available on the PNC Borsa app
        0
        • Above 7500 to 9750 soon these weeks bullish sentiments business development infrastructure expenditures stimulus package cause its stance growth economics of scales
          2
          • you are nostetadamoos
            1
        • may be buy or sell the stock but be very cautious before being vaccinated : some serious cases in Europe especially with young to intermediate people
          10
          Show previous replies (3)
          • GP GAPYes Im chief nurse teacher in a very big hospital. Not specialised in vaccine but i know a little bit about heath. And im a pro vaccine. But the rule we were givenby health autorities  was : Astra not for people under 55.
            1
          • Thanks for the advise.
            0
          • Jenny Goughlike dada
            0
        • This is moving now....at last! US approval coming.
          1
          • The cause behind the suspected vaccine side effects has been found. This is the opinion of a Norwegian expert group that examined the three healthcare employees who were admitted to hospital after being vaccinated with Astra Zeneca's vaccine. The vaccine triggered a strong immune reaction in the people. - I see no other reason than that it is the vaccine that triggers it, says the chief physician and professor Pål Andre Holme to VG. Sell off coming
            5
            • I guess that puts this Professor at odds with all the others looking at the data then.   Strange they were all healthcare employees.
              0
            • u shorting?
              1
          • AZN will go up & up
            2
            • Up today due to the £700m+ from disposal; vaccine is fine - EU politics.   Also good for those on kidney dialysis like a member of my family who can have this vaccine (& who has no ill effects). Only not for profit as long as pandemic is declared as one - but everyone likely to need annual jabs after that... great company.
              0
              • buy guys world health organization is giving advice to buy astrazeneca , you guys dum enough?
                2
                • Don't buyyyyyyy!!!!!
                  6
                  • Ive had the vaccine. It was great): All mainstream drug companies suffering as hospitals taken over with covid and thus everything else delayed and postponed.  Backlog will have to be caught up...  Also AZ only free for duration of pandemic... wont always be a pandemic but will likely need annual vaccines...  Hold but forget about it for a bit.
                    7
                    • So much good news today why it is going down oO
                      1
                      • What a *****stock! So disappointing!
                        0
                    • Good info about vaccine acceptancy
                      0
                      • It looks like purchasing volume are getting interesting....
                        0
                        • 11/02 earnings before market.
                          0
                          • how much possible drop after?
                            0
                        • good for long term
                          0
                          • Ruin that trash, because of that trash whole markate crashing.
                            4
                            • Naked Brand stock 🚀
                              2
                              • it has started to roll :)
                                1
                                • finaly
                                  0
                              • 8.000-8.100£
                                1
                                • if it goes above 7,600, Ciao
                                  2
                                  • sure, but when?
                                    1
                                  • sorry, I mean: yes, it woill go above, and NO, I definitely won't sell it at 7,6000. This is value stock. It should go way higher. It's only a matter of time.
                                    1
                                  • Anton Todorov ciao, I mean its going up (breaks resistance)
                                    0
                                • what is the forecast for AZ share?
                                  4
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.